Between 13 January and 10 November 2026, the US FDA posted 513 warning letters. They reached telehealth start-ups, online sellers, food importers and some of the best-known pharmaceutical names in India, China, South Korea and Japan.
BioSpectrum Asia read every one. The result is "513 Letters and a Message: What FDA's 2026 Warning Letters Tell Asia's Drugmakers", a whitepaper written for boards, quality heads and regulatory teams.
The numbers are hard to ignore. 59 letters went to Asia-Pacific companies and institutions, with India receiving 25 and China 22. Of the 121 letters on drug manufacturing quality, 45 went to sites in the region. And the median drug quality letter appeared on fda.gov just eight days after it was issued, often before the company's reply was even due.
The whitepaper goes beyond the counts. It shows how FDA enforced in coordinated waves, from compounded GLP-1 marketing to talc-containing products, and why the import alert now often arrives before the letter itself. Case files on Reliance Life Sciences, Eugia, Intas, Zydus, Dabur, Tianjin Kilo, Harbin Jixianglong and Huons set out what investigators found, in FDA's own words.
Inside the whitepaper
The message for Asia's drugmakers is clear: the distance between a gap in the records and a headline has never been shorter. The companies that do well in 2027 will be the ones that find the problems before an investigator does.
Read more and download the whitepaper →
https://biospectrumasia.com/fda-warning-letters-2026
